Press release
Odense, Denmark – September 28, 2026 – Inverna Therapeutics is pleased to announceits participation at BIO-Europe in Cologne.
Each year the event attracts a multitude of executives, investors, and strategic leaders who shape the biotech industry and are looking for new collaboration opportunities and partners.
CEO Poul Sørensen will be representing Inverna and look forward to presenting our portfolio and scientific progress in pursuit of new strategic partnerships and potential funding or licensing opportunities that can drive our business forward Inverna welcomes meeting requests through the respective partnering platforms.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
